Fig. 1 · Structure

Documents & Downloads

GW 9662

Cat. No. A11984 CAS 22978-25-2

PPARγ antagonist

GW 9662 is a selective PPARγ antagonist (IC50 values are 3.3, 32 and 2000 nM for PPARγ, PPARα and PPARδ respectively).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PPARγ (Cell-free assay) 3.3 nM
PPARα (Cell-free assay) 32 nM
PPARδ (Cell-free assay) 2 μM

GW 9662 Research Summary

This section summarizes 3 in vitro studies of GW 9662 from 2 published references. In vitro models include HEK293T cells; CTL cells.

GW 9662 In Vitro Studies

In HEK293T cells, GW 9662 at 5 µM for 18 hr did not significantly affect PPARγ transcription in a full-length PPARγ luciferase transcriptional assay. GW 9662 was not cytotoxic in HEK293T cells at 5 µM after 18 hr. In CTL cells, GW 9662 at 20 μM for 24 h had no effect on cell viability. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

PPARγ transcription in HEK293T cells

Cell-based study · HEK293T cells [1]

In HEK293T cells, GW 9662 treatment at 5 µM for 18 hr did not significantly affect PPARγ transcription in a full-length PPARγ luciferase transcriptional assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
full-length PPARγ luciferase transcriptional assayReported result 5 µM: GW9662 did not significantly affect PPARγ transcription[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM
Exposure duration
18 hr
Method
Ligand (5 µM) or vehicle control was added
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: GW 9662

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > T0070907 lowers basal activity of PPARγ (S5, S10, S11); Methods > Cell-based transcriptional reporter assays (S154); Fig. 1 legend (S253)

full-length PPARγ luciferase transcriptional assay: full-length PPARγ luciferase transcriptional assay; comparator: DMSO control — Results > T0070907 lowers basal activity of PPARγ (S5, S10); Fig. 1 legend (S253)

Cell viability in CTL cells

Cell-based study · CTL cells [2]

In CTL cells, GW 9662 treatment at 20 μM for 24 h had no effect on cell viability.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityReported result GW9662 (20 μM, 24 h): In CTL cells, GW9662 had no effect[2]

Literature-Reported Treatment Conditions

Treatment concentration
20 μM
Exposure duration
24 h
Method
treated
Reported limits
Not stated in the sentences used: vehicle, control.
Methods and source locations

Compound reported in the paper: GW 9662

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > PPARɣ inhibition suppresses CB13-mediated cell death in NSCLC cells (S61, S66); Materials and methods > Cell viability (S110)

cell viability: cell viability — Results > PPARɣ inhibition suppresses CB13-mediated cell death in NSCLC cells (S61, S66)

Cell viability in HEK293T cells

Cell-based study · HEK293T cells [1]

In HEK293T cells, the compound was not cytotoxic at 5 µM after 18 hr of treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityReported result were not cytotoxic at the concentrations tested (5 µM)[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM
Exposure duration
18 hr
Method
Ligand (5 µM) or vehicle control was added
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: GW 9662

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > T0070907 lowers basal activity of PPARγ (S4, S5, S9); Methods > Cell-based transcriptional reporter assays (S150, S154)

cell viability: cell viability; comparator: vehicle control — Results > T0070907 lowers basal activity of PPARγ (S9); Methods > Cell-based transcriptional reporter assays (S154)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 22978-25-2
Applications PPARγ antagonist
Formula C13H9N2O3Cl
Molecular Weight 276.68
SMILES
C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 48 mg/mL (173.48 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
8 mg/mL
Vehicle
5% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

GW 9662 Research References

  1. [1] Brust R, Shang J, Fuhrmann J, et al. A structural mechanism for directing corepressor-selective inverse agonism of PPARγ. Nat Commun (2018). PMID: 30409975 DOI: 10.1038/s41467-018-07133-w Source material
  2. [2] Kim TW, Hong DW, Hong SH. CB13, a novel PPARγ ligand, overcomes radio-resistance via ROS generation and ER stress in human non-small cell lung cancer. Cell Death Dis (2020). PMID: 33051435 DOI: 10.1038/s41419-020-03065-w Source material

Added to your cart

View Cart Checkout
Loading...